Kurosawa S, Esmon C T, Stearns-Kurosawa D J
Cardiovascular Biology Research, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.
J Immunol. 2000 Oct 15;165(8):4697-703. doi: 10.4049/jimmunol.165.8.4697.
The protein C pathway is a primary regulator of blood coagulation and a critical component of the host response to inflammatory stimuli. The most recent member of this pathway is the endothelial protein C receptor (EPCR), a type I transmembrane protein with homology to CD1d/MHC class I proteins. EPCR accelerates formation of activated protein C, a potent anticoagulant and antiinflammatory agent. The current study demonstrates that soluble EPCR binds to PMA-activated neutrophils. Using affinity chromatography, binding studies with purified components, and/or blockade with specific Abs, it was found that soluble EPCR binds to proteinase-3 (PR3), a neutrophil granule proteinase. Furthermore, soluble EPCR binding to neutrophils was partially dependent on Mac-1 (CD11b/CD18), a beta(2) integrin involved in neutrophil signaling, and cell-cell adhesion events. PR3 is involved in multiple diverse processes, including hemopoietic proliferation, antibacterial activity, and autoimmune-mediated vasculitis. The observation that soluble EPCR binds to activated neutrophils via PR3 and a beta(2) integrin suggests that there may be a link between the protein C anticoagulant pathway and neutrophil functions.
蛋白C途径是血液凝固的主要调节因子,也是宿主对炎症刺激反应的关键组成部分。该途径的最新成员是内皮蛋白C受体(EPCR),一种与CD1d/MHC I类蛋白具有同源性的I型跨膜蛋白。EPCR可加速活化蛋白C的形成,活化蛋白C是一种强效的抗凝剂和抗炎剂。当前研究表明,可溶性EPCR可与佛波酯(PMA)激活的中性粒细胞结合。通过亲和层析、与纯化成分的结合研究和/或用特异性抗体阻断,发现可溶性EPCR可与中性粒细胞颗粒蛋白酶-3(PR3)结合。此外,可溶性EPCR与中性粒细胞的结合部分依赖于Mac-1(CD11b/CD18),一种参与中性粒细胞信号传导和细胞间黏附事件的β2整合素。PR3参与多种不同过程,包括造血细胞增殖、抗菌活性和自身免疫介导的血管炎。可溶性EPCR通过PR3和β2整合素与活化中性粒细胞结合这一观察结果表明,蛋白C抗凝途径与中性粒细胞功能之间可能存在联系。